Cargando…

Ewing sarcoma from molecular biology to the clinic

In Europe, with an incidence of 7.5 cases per million, Ewing sarcoma (ES) is the second most common primary malignant bone tumor in children, adolescents and young adults, after osteosarcoma. Since the 1980s, conventional treatment has been based on the use of neoadjuvant and adjuvant chemotherapeut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dupuy, Maryne, Lamoureux, François, Mullard, Mathilde, Postec, Anaïs, Regnier, Laura, Baud’huin, Marc, Georges, Steven, Brounais-Le Royer, Bénédicte, Ory, Benjamin, Rédini, Françoise, Verrecchia, Franck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518617/ https://www.ncbi.nlm.nih.gov/pubmed/37752913 http://dx.doi.org/10.3389/fcell.2023.1248753

Ejemplares similares

Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing’s Sarcoma Tumor Growth
por: Mullard, Mathilde, et al.
Publicado: (2020)

The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth
por: Morice, Sarah, et al.
Publicado: (2020)

Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619
por: Lavaud, Mélanie, et al.
Publicado: (2021)

Involvement of the TGF-β Signaling Pathway in the Development of YAP-Driven Osteosarcoma Lung Metastasis
por: Morice, Sarah, et al.
Publicado: (2021)

The p53 Family Members p63 and p73 Roles in the Metastatic Dissemination: Interactions with microRNAs and TGFβ Pathway
por: Rodriguez Calleja, Lidia, et al.
Publicado: (2022)

Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1
por: Jacques, Camille, et al.
Publicado: (2016)

TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression
por: Lamora, Audrey, et al.
Publicado: (2016)

Tracking Targets of Dynamic Super-Enhancers in Vitro to Better Characterize Osteoclastogenesis and to Evaluate the Effect of Diuron on the Maturation of Human Bone Cells
por: Tesfaye, Robel A., et al.
Publicado: (2023)

Molecular Alterations Associated with Osteosarcoma Development
por: Ando, Kosei, et al.
Publicado: (2012)

Origin and Therapies of Osteosarcoma
por: Moukengue, Brice, et al.
Publicado: (2022)

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma
por: Lamoureux, Francois, et al.
Publicado: (2014)

LIM Kinases in Osteosarcoma Development
por: Brion, Régis, et al.
Publicado: (2021)

Implication of the p53-Related miR-34c, -125b, and -203 in the Osteoblastic Differentiation and the Malignant Transformation of Bone Sarcomas
por: Jacques, Camille, et al.
Publicado: (2020)

New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
por: Danieau, Geoffroy, et al.
Publicado: (2019)

Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?
por: Morice, Sarah, et al.
Publicado: (2020)

Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues
por: Lallier, Morgane, et al.
Publicado: (2021)

Antagonistic Functions of Connexin 43 during the Development of Primary or Secondary Bone Tumors
por: Talbot, Julie, et al.
Publicado: (2020)

TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment
por: Brion, Régis, et al.
Publicado: (2022)

Mechanisms of Resistance to Conventional Therapies for Osteosarcoma
por: Marchandet, Louise, et al.
Publicado: (2021)

Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases
por: Lamora, Audrey, et al.
Publicado: (2015)

Ribosomopathies: New Therapeutic Perspectives
por: Orgebin, Emilien, et al.
Publicado: (2020)

miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors
por: Jacques, Camille, et al.
Publicado: (2016)

Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma
por: Redini, Françoise, et al.
Publicado: (2015)

Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
por: Picarda, Gaëlle, et al.
Publicado: (2013)

SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression
por: Lézot, Frédéric, et al.
Publicado: (2020)

ICG-001, an Inhibitor of the β-Catenin and cAMP Response Element-Binding Protein Dependent Gene Transcription, Decreases Proliferation but Enhances Migration of Osteosarcoma Cells
por: Danieau, Geoffroy, et al.
Publicado: (2021)

Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration
por: Odri, Guillaume, et al.
Publicado: (2014)

Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment
por: Verrecchia, Franck, et al.
Publicado: (2018)

Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma
por: Georges, Steven, et al.
Publicado: (2018)

Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment
por: Pachva, Manideep C., et al.
Publicado: (2021)

Preliminary Results of the “Capasquelet” Technique for Managing Femoral Bone Defects—Combining a Masquelet Induced Membrane and Capanna Vascularized Fibula with an Allograft
por: Combal, Alexis, et al.
Publicado: (2021)

Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells
por: Faraahi, Z., et al.
Publicado: (2019)

Corrigendum to “Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells” [Bone 122 (May 2019) 82–92]
por: Faraahi, Z., et al.
Publicado: (2019)

The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
por: Corre, Isabelle, et al.
Publicado: (2020)

TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model
por: Moukengue, Brice, et al.
Publicado: (2020)

The First European Interdisciplinary Ewing Sarcoma Research Summit
por: Kovar, Heinrich, et al.
Publicado: (2012)

Cutaneous Ewing Sarcoma and Ewing Sarcoma of the Bone: Distinct Diseases
por: Tavakkoli, Montreh, et al.
Publicado: (2018)

The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma
por: Jin, Wook
Publicado: (2020)

Ewing's sarcoma of zygoma
por: Deshingkar, SA, et al.
Publicado: (2009)

Ewing's sarcoma of the mandible
por: Rao, B. H. Sripathi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pm9i1kouj9u0cv3q0s860t7cp2